LONG-TERM OVERALL SURVIVAL AND SAFETY OUTCOMES FROM THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 IMERGE TRIAL OF IMETELSTAT FOR LOWER-RISK MYELODYSPLASTIC SYNDROMES (SIE 2026) - Oct 6, 2026 - Abstract #DP079; Pres time: Sep 21, 2026; 07:00 PM - 08:00 PM; Location: AREA POSTER; "Subse- quent anticancer therapy (tx) was received by 57 (48.3%) of 118 IME-treated pts and 35 (59.3%) of 59 PBO pts in the safety analysis set, with 41 (34.7%) and 18 (30.5%), respec- tively, receiving luspatercept, and 12 (10.2%) and 12 (20.3%), respectively, receiving a hypomethylating agent (H- MA). The survival benefits with IME were maintained in pts who received subsequent tx. These analyses support the clinical benefit of IME in pts with RBC-TD LR-MDS."
Clinical • P3 data • Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Myocardial Infarction • Septic Shock
|
|
V. Santini1; R. Komrokji2; M. Savona3; M. Díez-Campelo4; P. Fenaux5; M. Sekeres6; Y. Madanat7; D. Valcárcel8; A. Jonášová9; P. Belohlavkova10; M. Mudge-Riley11; Q. Xia11; L. Sun11; J. Eid11; A. Zeidan12; U. Platzbecker13
|